Seres Therapeutics, Inc.

Thank you for standing by. My name is Alex and I will be your conference operator today. At this time, I would like to welcome everyone to the Q1 2024 SARA's Therapeutics Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, Press star 1 again. I would now like to turn the call over to Carlo Tanzi, investor relation. Please go ahead.

Thank you and good morning. Our press release for the company's first quarter 2020 financial results and business update became available at 7 a.m. Eastern time this morning and can be found on the investors and you section of the company's website. I'd like to remind you that we will be making forward-looking statements, including about the potential for BAUST, the timing and results of our clinical studies, future product candidates and development plans, our ability to generate additional capital, the sufficiency of cash to fund operations, and other statements, all of which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the risk factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so. On today's call, with prepared remarks, I'm joined by Eric Schaaf, Series Chief Executive Officer, Dr. Terry Young, Chief Commercial and Strategy Officer, Dr. Lisa Von Mulkey, Chief Medical Officer, and Marilla Thorell, Chief Financial Officer. In addition, Dr. Matthew Henn, Chief Scientific Officer, will be available to answer questions. With that, I'll pass the call to Eric.

Thank you, Carla, and good morning, everyone.